MangoRx said it 鈥渟trongly refutes鈥� claims made by Eli Lilly that it improperly copied blockbuster weight-loss medicines for sale on its telemedicine platform.
MangoRx was responding to Eli Lily after the drugmaker sued it and two other medical spas and online vendors earlier this week for selling products claiming to contain tirzepatide, the active ingredient in Lilly鈥檚 popular GLP-1 agonist drugs Zepbound and Mounjaro.
“Lilly filed three lawsuits yesterday against entities engaging in conduct that poses serious risks to patient safety,” an Eli Lilly spokesperson told 天美传媒app Technology.
“No one should ever be allowed to sell these untested, non-human grade or manipulated drugs to American consumers,” they added.
MangoRx is one of those implicated in the lawsuits as first reported by Reuters, as it sells a compounded version of tirzepatide in a weight loss product called Trim. FDA-approved drugs can be compounded under certain conditions such as if the original approved drug is in shortage and unavailable. Many patients seeking GLP-1 agonists turned to compound pharmacies as demand for Zepbound and Novo Nordisk鈥檚 Wegovy (semaglutide) far-outpaced supply, leading to shortages of the FDA-approved products. The FDA removed Lilly鈥檚 tirzepatide from its drug shortage list on 2 October, removing the previous qualification granted to compounding pharmacies to manufacture copycats of the drugs.
However, last week the FDA surprisingly said it would allow pharmacists to continue making compounded versions of tirzepatide while it reconsiders its decision to remove the drug from its nationwide shortage list. Compounders are still allowed to manufacture copycat versions of Wegovy, which is still on the shortage list.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEli Lilly, which has sued more than 20 medical spas, wellness centres, and compounding pharmacies over the past year, alleges MangoRx has improperly copied tirzepatide.
The Eli Lilly spokesperson confirmed that MangoRx unlawfully touts the efficacy of its manipulated tirzepatide knockoff, adding that is not “been clinically tested, let alone reviewed by FDA for safety or efficacy.”
According to MangoRx鈥檚 website, Trim uses an 鈥渋nnovative formula, using the power of Tirzepatide鈥� and 鈥渙ffers an effective and safe method for shedding excess weight.鈥� Eli Lilly claims there is no evidence that this compounded drug is safe and effective; the FDA has not approved an oral version of tirzepatide.
MangoRx said it 鈥渉as strong arguments against Eli Lilly鈥檚 claims and intends to vigorously defend itself in this matter.鈥� The company added it remains committed to offering patients innovative care 鈥渨hile striving to comply with federal, state and local regulatory guidelines鈥�.
Also involved in Eli Lilly鈥檚 most recent filing, were Pivotal Peptides and Genesis Lifestyle Medicine, with both companies allegedly selling tirzepatide-containing products to patients. Eli Lilly is looking to protect one of its most prized assets, with global sales of Mounjaro/Zepbound forecast to reach more than $32bn by 2030, as per analysis by GlobalData鈥檚 Pharma Intelligence Center.
GlobalData is the parent company of 天美传媒app Technology.
“These lawsuits reflect Lilly鈥檚 continued commitment to address the patient safety risks of mass-produced, untested, and manipulated drugs. We once again call upon state and federal regulators and law enforcement to take decisive action against those that threaten the health and wellbeing of Americans,” said Eli Lilly’s spokesperson.
Note: This article was updated on 23 October to include comment from an Eli Lilly spokesperson.
